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extracellular HSPs: The 
Complicated Roles of 
extracellular HSPs in immunity
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1 Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, 
2 Department of Medicine, Boston University Medical Center, Boston, MA, USA
Extracellular heat-shock proteins (HSPs) interact with the immune system in a very com-
plex manner. Many such HSPs exert powerful effects on the immune response, playing 
both stimulatory and regulatory roles. However, the influence of the HSPs on immunity 
appears to be positive or negative in nature – rarely neutral. Thus, the HSPs can act as 
dominant antigens and can comprise key components of antitumor vaccines. They can 
also function as powerful immunoregulatory agents and, as such, are employed to treat 
inflammatory diseases or to extend the lifespan of tissue transplants. Small modifications 
in the cellular milieu have been shown to flip the allegiances of HSPs from immunoreg-
ulatory agents toward a potent inflammatory alignment. These mutable properties of 
HSPs may be related to the ability of these proteins to interact with multiple receptors 
often with mutually confounding properties in immune cells. Therefore, understanding 
the complex immune properties of HSPs may help us to harness their potential in treat-
ment of a range of conditions.
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iNTRODUCTiON
Molecular chaperones are proteins that permit the maturation and correct folding of most of the 
proteome (1, 2). As such, they are found in all cellular organisms and seem essential for cellular life. 
Protein folding seems to require chaperones from a number of different gene families that appear 
to function at various stages in a concerted folding cascade. These proteins belong to the small 
heat-shock protein (HSP) family including Hsp27 and the larger 70 kDa HSP family including Hsp70 
as well as Hsp60, Hsp90, and Hsp110 families (3) (Table 1). We will discuss here, the mammalian 
immune responses to both prokaryotic (eubacterial) and eukaryotic HSPs under a range of con-
texts. The acronym HSP is derived from the early findings that some of these proteins are massively 
induced during proteotoxic stresses such as heat shock (4). Thus, the canonical functions of the HSP 
chaperones are in the folding of proteins during mRNA translation and in responding to protein 
unfolding crises in stressed cells (5).
However, HSPs also appear to possess functions outside the realm of protein folding, some of them 
acquired when they are released from cells to become extracellular HSPs (5, 6, 30, 31). HSPs have 
been observed in serum from human patients, pointing to their existence outside of cells, in living 
organisms (9). Among the first functions mooted for extracellular HSPs were in inflammation and 
immunity (23, 32). HSPs of each of the classes appeared to function in influencing the inflammatory 
TABLe 1 | immune/inflammatory roles for extracellular chaperones.
Chaperone Pro/anti-inflammatory Adaptive 
immunity?
Reference
Hsp27 Context − (5)
Hsp60 Context − (1, 6–8)
Hsp70 Context + (9–14)
Hsp90 Context ++ (14–18)
Hsp110 Pro +++ (19–22)
Grp94 Pro + (23, 24)
Grp170 Pro +++ (25–29)
Calreticulin Pro + (23, 24)
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and immunological balance in tissues (Table 1). The hypothesis 
of a pro-immune function for extracellular HSPs was derived 
primarily from studies utilizing molecular chaperone vaccines 
in cancer treatment (10, 23, 33). It was shown that HSPs from a 
number of chaperone families could be extracted from cancer cells 
while they were associated with a range of tumor peptide antigens 
(11, 33, 34). These HSP–peptide complexes could then be injected 
into hosts as anticancer vaccines, delivering a range of tumor-
derived antigens to the immune system and promoting antitumor 
immunity (19–22, 25–29). HSPs were, by the proponents of this 
approach, conventionally, viewed as playing a dominant role as 
promoters of immunity (32). In addition, a number of studies 
showed them to be pro-inflammatory mediators, and extravagant 
claims were made for molecular chaperones as activators of 
multiple facets of immunity. However, other investigators have 
demonstrated powerful anti-inflammatory roles for HSPs that 
we will discuss more fully, later in this manuscript (12, 35, 36). 
In addition, the properties of extracellular HSPs have now 
expanded to include powerful roles in processes outside the 
immune response. For instance, secreted Hsp90 has been shown 
to mediate wound healing and tumor metastasis (36, 37). Thus, 
extracellular HSPs appear to have come of age as major intercel-
lular signaling molecules in biology and medicine.
Some of the issues discussed here, particularly the role of 
HSPs in antigen presentation, have been mentioned in a previous 
review (38). Here, however, we focus mainly on the potentially 
confound pro- and anti-inflammatory roles of HSPs and discuss 
how these properties can be manipulated toward clinically useful 
outcomes in both treatment of autoimmune conditions and in the 
deployment of chaperone anticancer vaccines.
ReLeASe OF HSPs iNTO THe 
eXTRACeLLULAR MiCROeNviRONMeNT
Structural considerations would tend to make one skeptical 
regarding the possibility of HSP secretion into the extracellular 
milieu. HSP family proteins lack an N-terminal hydrophobic sig-
nal sequence, characteristic of most secreted proteins, and thus, 
cannot be released from cells by the conventional secretion path-
ways. However, a number of non-canonical secretion pathways 
exist, many of which are employed by cytokines to gain access 
to the extracellular milieu. These eccentric mechanisms include 
release of the polypeptides via secretory lysosomes, a pathway 
utilized in the release of IL-1β from inflammatory cells  (39). 
Hsp70 has been shown to be secreted from a number of cells in 
free form by a similar pathway, through a mechanism requiring 
the lysosomal pH gradient (31, 40). Indeed, Hsp70 is cosecreted 
from cells along with the lysosome resident protein LAMP1 (31). 
Hsp70 is also released from a range of other cells including tumor 
cells, reticulocytes, peripheral blood mononuclear cells, B cells, 
and dendritic cells in various types of lipid vesicles [reviewed by 
De Maio (41) and Vega et al. (42)]. These vesicles may include a 
variety of lipid-bounded structures, including ectosomes that are 
vesicles derived from the plasma membrane and that may contain 
cytosolic proteins as well as exosomes. Formation of exosomes 
is a complex process including the internalization of portions 
of the plasma membrane and subsequent release of exosomes 
containing a variety of previously intracellular proteins, includ-
ing HSPs (43). The exosomal pathway is also utilized by some 
cells for IL-1β secretion (44). HSP-containing exosomes have a 
wide array of properties including both immunostimulatory and 
immunosuppressive functions, depending on the protein content 
of the exosome, cell of origin, and target cell (45–47).
Heat-shock proteins, therefore, can be secreted from a variety 
of cells in free form and in membrane-bounded particles. In addi-
tion, they can be released from cell undergoing necrotic death 
when membranes are disrupted, and the HSP can leak passively 
out of the cells (48). Hsp70 released in such a way has been shown 
to be strongly immunostimulatory.
HSPs AS CARRieRS OF TUMOR 
ANTiGeNS AND MeDiATORS OF 
iMMUNiTY
Adaptive immunity
Molecular chaperones are unique immune modulators in that 
they can associate with a wide range of antigenic peptides and 
facilitate their delivery to antigen-presenting cells (APCs) (11, 
13, 23, 33, 34). This property has proven to be desirable in the 
preparation of anticancer vaccines. Only a relatively small num-
ber of tumor antigens have been characterized, and we presume 
that this group represents a small minority of the real repertoire 
of unique cancer-derived antigens. Thus, chaperones, such as 
Hsp70, can be considered to “sample” the antigenic milieu of the 
malignant cell on encountering processed peptides in vivo and 
can be used to carry this sample into the APC during immuniza-
tion (Figure 1). Such HSP-containing vaccines have proven to be 
highly effective in studies in experimental tumor systems in mice, 
in which they can lead to tumor regression associated with the 
generation of specific immunity (10, 13, 14, 20, 49–51). Issues in 
the preparation of the vaccines, which may influence the clinical 
effectiveness of vaccines, include the degree to which antigens 
can be retained by the chaperone and the affinity for the peptide 
during immunization and entry into APC (11, 14, 52).
Cross-presentation is a process by which extracellular antigens 
can gain access to the MHC class I pathway, a mechanism normally 
reserved for processing and presenting endogenous antigens (38). 
Efficient antigen cross-presentation is very important for vaccine 
effectiveness as MHC-I–peptide complexes permit recognition 
of cells bearing the complexes and killing by CD8+ cytotoxic 
FiGURe 1 | immune activation by HSP-based anticancer vaccines.  
The HSP–peptide complexes that comprise the anticancer vaccine are shown 
to interact with APC after vaccination of host. The vaccines can efficiently (1) 
cause cross-presentation of tumor antigen and, thus, prime CD8+ T 
lymphocytes as well as activating CD4+ T cells through the (2) class II 
pathway. However, many investigations suggest that HSPs may not have 
major effects on (3) inflammatory signaling and may require combination with 
agents with adjuvant activity or inflammatory cell killing. Gray spheres  
indicate nuclei.
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T lymphocytes (53). Interestingly, Hsp90 appears to protect the 
integrity of internalized antigens associated with it, to trigger 
cross-presentation, and to carry antigens deep into the cell, 
penetrating the plasma membrane and endosomal membranes, 
and delivers chaperoned peptides to cytoplasmic proteasomes for 
processing (15, 16).
Although CD8+ T cells can be triggered by DC to recognize 
antigens after cross-presentation, in the absence of further sig-
nals, such T cells are unable to kill their targets. Other inputs are 
required for full activation (54, 55). The principal pathway used 
by APC for sampling external antigens is the MHC class II path-
way. MHC class II molecules are found only on the surfaces of 
immune cells. The class II pathway involves the uptake of antigens 
by receptors on DC, processing of such antigens in the lysosomal 
compartment, transport of vesicles containing antigen–MHC-II 
complexes to the cell surface, and presentation to CD4+ T lym-
phocytes. Hsp90 is able to carry associated antigens into APCs 
and direct them into the class II pathway as well as facilitate cross-
presentation. The choice of direction regarding entry of antigens 
into the class I/cross-presentation or class II pathways appears to 
usually depend upon the antigen-binding receptor that mediates 
triage between the two presentation systems (56, 57). However, 
Hsp90 appears neutral in this regard and increase penetration of 
associated peptides into either pathway (17, 18). One important 
activity governed by the MHC class II pathway is a process called 
dendritic cell licensing (54). In this mechanism, CD4+ T cells that 
recognize the antigen on a particular DC produce a reaction in 
the APC that permits it to activate CD8+ cells that interact with 
the same APC. Interaction of the T cell receptor on the CD4+ 
T cell triggers the expression of CD40 ligand (CD40L) that can 
bind the CD40 counter receptor on the DC and induce expression 
of inflammatory cytokines, such as TNFα and IL-12 as well as 
stimulatory coreceptors, like CD80 and CD86 (58, 59). These 
coreceptors cooperate with MHC class I in fully activating the 
CD8+ T cell through the T cell receptor. Thus, HSP–peptide 
complexes become internalized and trigger both the MHC class 
I and II pathways and may permit DC licensing to occur (17, 
18). Our findings that HSPs can facilitate uptake of individual 
Ova antigens through the MHC-I and MHC-II pathways suggest 
the possibility of HSP–antigen complex could mediate DC licens-
ing, although this has not yet been formally proven. Homing of 
CD8+ T cells toward licensed DC may involve surface chemokine 
receptor CCR5, a process strongly stimulated by chemokines, 
CCL3 and CCL4 (54). It has been shown in Lewis lung carcinoma 
cells, in vivo, that antitumor immunity was activated along with 
release of chemokines CCL2, CCL5, and CCL10, by a mechanism 
dependent on Hsp70 and TLR4 (60).
inflammation and innate immunity
On exposure to prokaryotic cells or cell products, a separate 
branch of immunity known as innate immunity is stimulated. 
In this process, molecules characteristic of individual pathogens 
including contrasting types of viruses and bacteria, known as 
pathogen-associated molecular patterns (PAMPs) herald the 
infection and prime the immune response (61). Then, PAMPs 
interact with specific receptors on macrophages or DC, known as 
pattern recognition receptors (PRR), and trigger innate immu-
nity. Best known among the PRR are the toll-like receptors (TLR) 
that can couple binding of individual PAMPs to intracellular 
signaling pathways and gene expression programs (62, 63). Most 
notable among the mechanisms triggered by PRR occupation are 
the NKK and MAP-kinase pathways that influence inflammatory 
transcription through activation of factors, such as NFκB and 
IRF3 (64). This process can lead to synthesis of costimulatory 
molecules, such as CD80, and activating cytokines such as TNFα 
and IL-12 that synergize with MHC class I signaling in generation 
of active and long lived CTL (54). It is not clear to what extent HSPs 
derived from prokaryotes might function as PAMPs, although 
their extreme conservation across all cellular species would seem 
to argue against this. HSPs derived from mycobacteria are, how-
ever, recognized by the mammalian immune response and invoke 
powerful immunity to the extent that they have been described as 
superantigens (65). The mechanisms by which prokaryotic Hsp60 
activates immunity are not clear but could involve PRR, such as 
TLRs, or other mechanisms.
It has also been shown that some molecules released from 
damaged and dying cells, such as uric acid and high mobil-
ity group box 1 protein (HMGM1), may trigger a form of 
sterile innate immunity, and such molecules are referred to as 
damage-associated molecular patterns (DAMPs), in order to 
suggest a functional similar to PAMPs (66, 67). Thus, DAMPs 
are thought to trigger innate immunity by binding to PRR and 
triggering inflammatory signaling cascades. Hsp70 was widely 
reported to function as a DAMP and to trigger innate immunity 
through the TLR2 and TLR4 pathways (32). Although this 
field has run into some controversy, the majority of findings in 
studies carried out in vivo over the past 15 years suggested that 
Hsp70, through interaction with TLR4, could potentially act as 
4Calderwood et al. Complex Roles of HSPs in Immunity
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a DAMP (68). This area has been recently reviewed in depth 
(69). In addition to Hsp70, extracellular Hsp27 has recently 
been shown to cause both inflammatory and anti-inflammatory 
effects (5).
SOMe ANTi-iNFLAMMATORY AND 
iMMUNOReGULATORY eFFeCTS 
OF HSPs
Although prokaryotic HSPs can trigger a powerful immuno-
dominant response in animals, most reports indicate that their 
effects are generally not pro-inflammatory, and the antibodies 
and T cells activated in the response had anti-inflammatory 
properties (69–71). Curiously, the epitopes that T cells respond 
to in mycobacterial Hsp60 were conserved with mammalian 
HSPs, and such cells recognized and responded to epitopes in the 
mammalian proteins. Prokaryotic Hsp60, therefore, did not seem 
to act as a PAMP (7). In addition, although HSPs were shown to 
interact with TLRs, such PRR often provoked anti-inflammatory 
signaling (8). For instance, Hsp60-derived peptides interacted 
with TLR2 on regulatory T cells (Tregs) leading to an immuno-
suppressive response. In addition, purified mycobacterial Hsp70 
inhibited the maturation of DC (72, 73). Intracellular HSP levels 
were shown to increase in inflamed tissues and HSP-derived 
peptides expressed on the cell surface and appeared to activate 
Treg responses, thus mediating immunoregulatory functions 
(74). No studies, to date, have shown direct interactions between 
HSPs and TLRs, and in fact, attempts to show such binding 
have been negative (73, 75). The extracellular influences on TLR 
activity that have been reported may, therefore, be indirect and 
likely dependent on primary interactions of the HSP with other 
receptors on immune cells, such as the scavenger receptors (SR), 
followed by recruitment of TLR (64). The powerful immune 
effects of non-mammalian Hsp60 may also involve mechanisms 
independent of TLRs, and it has been suggested that the immune 
response may be genetically programmed to respond to such 
chaperones (76).
Interestingly, some of the studies applying HSP vaccines to 
cancer therapy indicated that, although there was significant 
activation of antitumor CTL by these agents, these were followed 
by a delayed Treg response. These findings suggest contrasting 
effects of the vehicle (HSP) and cargo (antigenic peptide) com-
ponents of chaperone vaccines on immunity. These data might be 
interpreted as, suggesting that, while tumor antigens chaperoned 
by the HSPs trigger antitumor immunity, processed peptides 
from the HSP component of the vaccine led to a suppression of 
immunity. Using the chaperone vaccines at lower doses appeared 
to favor induction of CTL over the immunoregulatory response, 
perhaps by reducing the levels of HSP-derived peptides below a 
threshold (77, 78). It would seem that most chaperone vaccines, 
although efficiently triggering external tumor antigen presenta-
tion, do not deliver the inflammatory signal required to overcome 
antigenic tolerance (Figure 1). Such vaccines might be improved 
by use of adjuvants or pro-inflammatory forms of therapy, as 
discussed below.
wHeN HSPs BeCOMe PRO-
iNFLAMMATORY FACTORS
One notable finding observed in multiple investigations of HSPs 
was that, even in studies where an inflammatory response to 
HSPs was not detected, the chaperones could strongly amplify 
responses to PAMPs, such as LPS (79). Mycobacterial Hsp65, 
a protein discussed in the last section as provoking generally 
immunomodulatory responses, when covalently fused to anti-
genic polypeptides produced a potent vaccine that generated 
effective CTL even in the absence of adjuvant (80). In addition, 
the combination of Hsp70 elevation in target tissues with thera-
pies leading to necrotic cell killing led to a profound stimulation 
of inflammation and CTL killing that could lead to tumor rejec-
tion (81). This approach involved, after elevation of tissue Hsp70, 
targeting the normal tissues of origin with treatments that led 
to inflammatory modes of cell killing. This combined treatment 
resulted in the regression of distant, transplanted tumors (81). 
The findings observed in these studies were that, for instance, in 
prostatic tissue, cell killing by fusogenic viruses in the presence 
of elevated Hsp70 led to induction of the cytokines IL-6 and 
TGF-β, resulting in generation of highly inflammatory IL-17 
and tumor rejection by antigen-specific CTL (82). This effect 
seemed to depend on generation of IL-6 by the combination of 
high tissue levels of Hsp70 and inflammatory death. However, in 
similar studies on pancreatic tissues, combination of Hsp70 and 
lytic virus failed to generate IL-6 and led to generation of a Treg 
response and continued growth of pancreatic carcinoma (82). 
Thus, the balance between immunoregulatory and immunogenic 
responses of Hsp70 appears to be poised on a knife-edge, influ-
enced by the tissue type and mode of cell killing.
It is well known that the mode of cell death has a powerful 
influence on inflammation and immunity in interacting APC 
(83). For instance, when cells die by an apoptotic mechanism, 
their intracellular contents remain enveloped by an external 
membrane and, thus, are not released into the environment 
to trigger inflammation (Figure  2). In addition to this, many 
apoptotic cells expose “eat me” signals, such as the phospholipid 
phosphatidylserine on the surface, triggering engulfment by 
macrophages and leading to immunosuppression (84, 85). 
Additional anti-inflammatory signals emanating from apoptotic 
cells may include the release of AMP from the apoptotic cell (86). 
In necrotic cell death, cell membranes become permeabilized, 
the intracellular milieu becomes externalized, and DAMPs, 
such as HMGB1, urate, and nucleic acids, released in this way 
become accessible to detection by neighboring macrophages or 
DC (85). It should be noted that the response of phagocytic cells 
to apoptotic bodies is complex and depends on the nature of the 
dead or dying cells and the surface densities of “eat me” or “don’t 
eat me” signaling molecules that are cell specific. In addition, in 
late apoptotic cells that have failed to be phagocytosed at an early 
stage, membranes become permeabilized. Therefore, such late 
apoptotic cells acquire some of the properties of necrotic cells, 
permitting release of DAMPs and switching the effects of the cell 
corpses on engulfing phagocytes toward a more immunogenic 
influence (85, 87).
FiGURe 3 | HSP receptors. HSP receptors include SREC-I and LOX-1 that 
mediate (1) endocytosis and, thus, presentation of antigens to APC. Hsp70 
can also (2) trigger signaling through the TLR4 pathway in a range of cells. (It 
is not clear whether HSPs can interact directly with TLRs or whether the 
primary interactions are through other receptors.) Effects of Hsp70 on TLR4 
signaling can be modulated by binding to either Siglec-14 that activates TLR4 
signaling or other Siglec family members, such as Siglec-5, that activate the 
pathway. Hsp90 can also (3) activate wound healing responses, which may 
play key roles in inflammation, through binding to CD91. Hsp70 triggers (4) 
phagocytosis, a property that may be important in its immune functions, 
through currently unknown mechanisms. Gray ovals indicate nuclei.
FiGURe 2 | Contrasting effects of cell corpses resulting from apoptotic 
and necrotic cell killing on immunity. Apoptotic cells, depicted here with 
surface blebs, externalize the phospholipid phosphatidylserine to the outer 
leaflet of the plasma membrane leading to anti-inflammatory signaling and 
suppression of immunity. Necrotic cells depicted here with compromised 
membranes release DAMPS, such as HMGB1 (small orange spheres), and 
acquire net negative charge. Nucleic acids (pink lines) become located to the 
cell surface. Necrotic cells often trigger release of inflammatory cytokines, 
such as IL-6 and TNFα. HSPs, such as Hsp70, trigger the phagocytosis of 
dead mammalian cells as shown here, although the mechanisms involved in 
such stimulation are currently not clear. Gray spheres indicate nuclei.
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It is not clear in which way extracellular HSPs might synergize 
with the extruded contents of necrotic cells in activating immu-
nity, although increased capacity for engulfment by immune 
cells which is triggered by Hsp70 might amplify inflammatory 
functions (88–90). The earlier studies of Todryk et  al., in fact, 
indicated that extracellular Hsp70 decrease DC maturation 
and increase capacity for engulfment of antigenic materials by 
the immature APC (91). Phagocytosis is a complex process and 
involves the formation of a broad synapse type structure between 
the engulfing cell and the mammalian cell body of prokaryotic 
cells. Multiple receptors appear to make contact between the cells. 
Interestingly, in C. elegans this process has been shown to require 
the surface receptor CED-1 (92). Both, mammalian scavenger 
receptor associated with endothelial cells (SREC-I) and cluster 
of differentiation 91 (CD91) possess sequence similarities to 
this protein, suggesting some involvement in phagocytosis and a 
potential mechanism for HSPs in this process (93). In addition, 
necrotic cells can supply signals to augment the immune effects 
of HSPs through release of HMGB1, a ligand for TLR4, and exter-
nalized nucleic acids that might interact with TLR3 or TLR9 and 
trigger inflammatory signaling (85) (Figures 2 and 3).
POTeNTiAL MeCHANiSMS – CeLL 
SURFACe ReCePTORS AND CeLL 
SiGNALiNG PATHwAYS
Most evidence suggests that the biological effects of extracel-
lular HSPs are mediated through cell surface receptors (24, 94) 
(Figure 3). Thus, some of the clues to the properties of extracel-
lular HSPs may lie within the interactions of these chaperones 
with these receptors and the unleashing of their embedded 
signaling cascades. The first surface receptor reported to bind to 
HSPs was CD91 also known as Low density lipoprotein receptor-
related protein 1 (LRP1), the alpha-2-macroglobulin receptor 
(A2MR), and apolipoprotein E receptor (APOER) (24). This 
high molecular weight receptor was shown originally to bind 
to LDL and, as its possession of multiple names suggests, a wide 
range of (over 30) other extracellular structures (94). CD91 is 
expressed most abundantly in vascular smooth muscle cells and 
in hepatocytes. There has been some skepticism regarding its 
expression in APC, such as DC, and, therefore, its potential role 
in immune responses involving the HSPs (95). However, there 
seems little doubt that CD91/LRP1 is a bona fide HSP recep-
tor, and this protein appears to play key roles in, for instance, 
responses to Hsp90α in the wound healing response and in 
tumor metastasis (36, 37).
It was next shown that Hsp70 could associate with lectin-
type oxidized LDL receptor (LOX-1), a receptor found on the 
surfaces of human DC and that such binding could mediate 
cross-presentation of peptide cargo associated with this HSP, 
leading to CD8+ lymphocyte-mediated immunity (75). LOX-1 
is the product of the oxidized low-density lipoprotein receptor 1 
(ORL1) gene expressed most abundantly in vascular endothelial 
cells, macrophages, and DC (96). Although LOX-1 belongs to 
the C-type lectin receptor family, it also clusters with the SR, a 
group of proteins that have, in common, the ability to bind to 
covalently modified LDL molecules, such as oxidized LDL and 
6Calderwood et al. Complex Roles of HSPs in Immunity
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acetylated LDL (97). Furthermore, exploration of the SR family 
indicated significant interaction of Hsp70 with at least two other 
members, including SREC-I, encoded by the SCARF1 gene 
and Stabilin-1/FEEL-1 (encoded by the STAB1 gene) (73, 98). 
SREC-I/SCARF1 was able to bind to Hsp70 and Hsp90 in DC 
and mediated cross-presentation of associated tumor antigens, 
leading to activated CTL (13, 17). Murine bone marrow derived 
DC appeared to utilize both LOX-1 and SREC-I/SCARF1 in 
interacting with Hsp90–peptide complexes (17, 75). In addi-
tion, SREC-I was also shown to mediate the uptake of antigens 
chaperoned by Hsp90 into the Class II pathway and stimulate 
activation of CD4+ T lymphocytes (18). The SR are regarded as 
receptors that respond to cellular debris including cell bodies, 
the remains of endogenous proteins spilled into the extracel-
lular milieu, and the residue from invading pathogens. As such, 
the SR might be regarded as good choices for receptors with 
which APC might sample the extracellular environment (93). 
Stabilin-1 appears to be only sparsely expressed on the surface 
of DC and appears to function mostly in intracellular trafficking 
(99). Thus, there appeared little doubt that that the SR could 
bind to HSP-PC and mediate presentation of peptide cargo 
(17, 18). However, the nature of the receptors that might respond 
to HSPs and modify the inflammatory response still required 
investigation.
Many reports suggested that TLRs, particularly TLR2 and 
TLR4, might mediate inflammatory responses to HSPs in an up 
or down manner (32, 76). However, as mentioned above, attempts 
to demonstrate direct binding of HSPs to TLRs have not been 
generally successful (73, 75). Thus, HSP interaction with TLRs is 
likely to be an indirect one. It was shown, recently, that SREC-I/ 
SCARF1 could interact with TLR4 on the surface of mouse mac-
rophages (64). Interestingly, both LPS and Hsp90 could mediate 
this complex interaction and lead to the sequestration of TLR4 in 
lipid raft domains (64). In the case of LPS, encasement of SREC-I–
TLR4 complexes within lipid rafts was required for activation of 
signaling through the NFκB and MAP-kinase cascades, resulting 
in inflammatory cytokine secretion. Significantly, exposure to 
Hsp90, although leading to SREC-I–TLR4 colocalization, failed 
to trigger the inflammatory cascade through this mechanism. 
Alternative pathways of inflammatory suppression by Hsp90 
may, thus, be involved (64).
Recent studies have also suggested that another receptor 
family, sialic acid-binding immunoglobulin-like lectins (Siglecs) 
may participate in inflammatory responses resulting from bind-
ing to HSPs (100). These receptors have been shown to bind to 
conjugated sugar residues in the cell coats of adjacent cells and 
generally suppress inflammation. Suppression of inflammation 
by these receptors involves immunoreceptor tyrosine-based 
inhibitory motif (ITIM) sequences in the intracellular domain 
that recruit anti-inflammatory proteins after ligand-triggered 
tyrosine phosphorylation (100). Upon activation, Siglec receptors 
have been shown to directly associate with TLRs and inhibit TLR-
mediated activation of inflammatory signaling cascades, such as 
the NFκB pathway (101). Interestingly, recently, it was shown that 
two human Siglecs, Siglec-5 and Siglec-14 each, bind to Hsp70 
(102). What was most intriguing about these interactions was 
that, while Siglec-5 contained the expected ITIM domain and 
repressed anti-inflammatory signaling through quenching NFκB, 
Siglec-14 appeared to have acquired a domain that binds proteins, 
such as DAP12, containing an intracellular immunoreceptor 
tyrosine-based activating motif (ITAM) that stimulated release 
of inflammatory cytokines (102, 103). Differential expression 
of members of the Siglec family might, thus, either amplify or 
suppress the HSP regulated activities of cell surface TLR and 
inflammatory signaling through mediation of the NFκB pathway. 
A further property of extracellular HSPs mentioned above, that 
may play a key role in their immune functions, is their ability 
to trigger phagocytosis. However, the mechanisms and receptors 
involved in this process have not been well characterized and fur-
ther experiments will be required to understand the mechanisms 
involved (Figure 3).
Thus, responses to extracellular HSPs appear to involve the 
cooperative or confounding outputs of a range of cell surface 
receptors that together may determine their influence on immune 
reactions within tissues. To date, however, we have not been able 
to identify a dedicated high-affinity HSP receptor. Dedicated 
receptors, such as the insulin receptor, are often able to pick up 
tiny concentrations of ligands, often with affinities in the range of 
10−9–10−10M, with exquisite selectivity. For HSPs, we have identi-
fied, so far, only “hand me down” receptors that also bind a large 
range of other ligands with moderate affinity. It remains to be 
determined if dedicated HSP receptors will be found in immune 
cells of mammalian species.
CONCLUSiON
The intracellular roles of HSPs in protein folding have been 
conserved since the dawn of cellular life (3). However, the HSPs 
also appear to have acquired key roles in the immune systems of 
animals early during evolution, and these roles are preserved in 
modern animal species (104). Such HSPs can capture intracel-
lular antigens and present them to APC, mediating the cross-
priming of recipient cells. In addition, HSPs, when processed 
and presented on the APC cell surface, can activate Treg cells 
and inhibit immunity and inflammation. Their effects on the 
immune system are, thus, bivalent. In the presence of PAMPs 
or tissues undergoing necrosis, Hsp70, in particular, becomes a 
strong inflammatory agent. The precise nature of the responses 
elicited by extracellular HSPs may, therefore, depend upon the 
particular tissue milieu within which they are released and the 
identities of the receptors on the surfaces of immune cells that 
encounter them.
OUTSTANDiNG QUeSTiONS AND 
POTeNTiAL ADvANCeS
 (1) Many of the immune-active HSPs are members of different 
gene families, with only a modicum of structural similarity 
(Table  1). However, each chaperone appears to be recog-
nized by similar families of receptors, including SR and the 
LDL receptors, despite their sequence dissimilarity (94). 
Understanding the structural basis for extracellular HSP 
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recognition by these and potentially new classes of recep-
tors would be an advance in determining the roles of the 
chaperones in immunity and predicting novel recognition 
structures. However, this has been an open question for a 
number of years now and research is ongoing.
 (2) It is becoming apparent that members of individual HSP gene 
families have distinct properties. For instance, only Hsp90α 
is secreted from cells and the other major isoform, Hsp90β, is 
mostly retained within the cell (36). It will be enlightening to 
learn whether such specificity in extracellular function holds 
for other HSP families.
 (3) We have, in recent years, acquired some understanding of 
how these “leaderless” proteins gain access to the extracel-
lular microenvironment in intact cells (see Release of HSPs 
into the Extracellular Microenvironment), although it will 
be invaluable to gain a more concerted understanding of 
mechanisms of HSP secretion.
 (4) We will continue the search for HSP receptors in immune 
cells, their expression patterns and their connection to 
inflammatory and anti-inflammatory responses to both 
endogenous HSPs and prokaryotic paralogs (94). It is likely 
that a major key to understanding how chaperones trigger 
immune responses and the direction of such responses 
depends on understanding the combinatorial effects of the 
multiple receptor families.
 (5) It seems clear that many HSPs, although capable of effi-
cient transport of antigenic peptides within chaperone 
vaccines, do not on their own deliver a second signal 
for APC maturation, thus reducing their effectiveness as 
stand-alone agents. In order to break immune tolerance 
to tumor antigens, chaperone vaccines might be best 
deployed in cancer therapy in combination with PAMPs, 
such as double stranded RNA or unmethylated CpG motifs 
or checkpoint inhibitors such as anti-CTLA4 (105, 106). 
Alternatively, vaccines could be used with agents, such as 
ionizing radiation, that can cause necrotic killing and sub-
sequent inflammatory effects in tumors (including release 
of intracellular DAMPs) thus leading to immune rejection 
of the cancers (10).
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